OPDUALAG

This brand name is authorized in Austria, France, Croatia, Israel, Italy, Lithuania, United States

Active ingredients

The drug OPDUALAG contains a combination of these active pharmaceutical ingredients (APIs):

1 Nivolumab UNII 31YO63LBSN - NIVOLUMAB

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. Nivolumab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands. In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth. Read about Nivolumab

2 Relatlimab UNII AF75XOF6W3 - RELATLIMAB

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OPDUALAG Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FY02		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FY Combinations of monoclonal antibodies and antibody drug conjugates
Discover more medicines within L01FY02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 62235699
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9285
Country: IT	Agenzia del Farmaco	Identifier(s): 050359013
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095546
Country: US	FDA, National Drug Code	Identifier(s): 0003-7125